Loading patent…
AssigneeCreagene Inc.
InventorsDong Sung Lee, Woo Bok Lee, Choon Ju Jeon, Yong Soo Bae
Estimating the term…
A method for analyzing the prevention and treatment efficacy of a dendritic cell-derived immunotherapeutic for prostate cancer using an animal model carrying tumors expressing a human prostate cancer-specific antigen includes either administering to a normal non-human animal dendritic cells to be analyzed, or administering to a normal non-human animal a cancer cell line expressing the human prostate cancer-specific antigen to induce cancer in the normal non-human animal; administering to the animal the cancer cell line expressing the human prostate cancer-specific antigen to induce cancer in the animal when the dendritic cell administering step was performed, or administering to the animal with cancer dendritic cells to be analyzed when the human prostate cancer-specific antigen expressing cell line administering step was performed; and determining the prevention and treatment efficacy of the dendritic cells as immunotherapeutics for prostate cancer by measuring the formation or growth of cancer cells originated from the cancer cell line in the animal.
A method for analyzing the prevention and treatment efficacy of a dendritic cell-derived immunotherapeutic for prostate cancer using an animal model carrying tumors expressing a human prostate cancer-specific antigen, which comprises the steps of:
The method according to claim 3, wherein the rodent is a mouse (Mus musculus).
The method according to 1, wherein the human prostate cancer-specific antigen is PCA (prostate cancer antigen), PSCA (prostate stem cell antigen), PSA (prostate-specific antigen), PAP (prostate acid phosphatase) or PSMA (prostate-specific membrane antigen).
A mouse-derived renal cancer cell line (RENCA) expressing a human prostate cancer-specific antigen, characterized in that the human prostate cancer-specific antigen is PCA (prostate cancer antigen), PSCA (prostate stem cell antigen), PSA (prostate-specific antigen), PAP (prostate acid phosphatase) or PSMA (prostate-specific membrane antigen) and the renal cancer cell line is not a prostate cancer cell-derived one.
Dependencies are inferred from the claim text.